Biotechnology (21) | Waiver Agreements (21)

Browse by Company

Recent Contracts

Waiver dated June 13, 2022 (TENAX THERAPEUTICS, INC., Filed With SEC on June 16, 2022)
Waiver and Amendment Letter, dated May 23, 2022 (OPGEN INC, Filed With SEC on May 24, 2022)
Form of Waiver Agreement (AzurRx BioPharma, Inc., Filed With SEC on May 13, 2022)
Form of Waiver (CLEVELAND BIOLABS INC, Filed With SEC on March 22, 2022)
Form of Waiver (AzurRx BioPharma, Inc., Filed With SEC on February 7, 2022)
Waiver and Amendment between Qualigen Therapeutics, Inc. and Alpha Capital Anstalt, dated November 29, 2021 (RITTER PHARMACEUTICALS INC, Filed With SEC on December 1, 2021)
Waiver and Defeasance Agreement (ADiTx Therapeutics, Inc., Filed With SEC on August 30, 2021)
Form of Waiver Agreement, dated as of February 3, 2021, by and between Ocuphire Pharma, Inc. and the Holder(s) (REXAHN PHARMACEUTICALS, INC., Filed With SEC on February 4, 2021)
Fee Waiver Letter, dated January 31, 2021 (Leisure Acquisition Corp., Filed With SEC on February 2, 2021)
Waiver, dated January 20, 2021, by and among Cerevel Therapeutics Holdings, Inc. and the investors party thereto (ARYA Sciences Acquisition Corp II, Filed With SEC on January 21, 2021)